It’s almost 7 months that the world first faced deadly coronavirus.
Coronavirus has infected more than 13 million people and cause lacs of fatalities.
Almost all the developed and developing countries are in rush to make Corona vaccine.
Now Oxford University Researchers may now be first company to claim the positive outcome from phase 1 and 2.
Yesterday the news of vaccine phase 1 and 2 wave released. Now after a lot of casualties, one positive news comes that the antibodies spiking up vaccine, gives of positive hopes to everyone around the world.
Studies say that the vaccine, AZD1222 was able to produce a dual response in volunteers aged between 18-55.
“Now what this vaccine does particularly well is triggered both arms of the immune system in addition to neutralizing antibodies which other vaccines do, we also see a very strong T-cell response,” says Professor Adrian Hill, Director of the Jenner Institute, Oxford University.
Richard Horton, the editor of the UK-based science journal ‘The Lancet’ also noted that “the vaccine is safe, well-tolerated, and immunogenic.”
The researchers are still proceeding with phase three of trials.
In collaboration with Oxford University, Astrazeneca and British Swedish pharma has struck deal with private vaccine manufacturer, Serum Institute of India to produce 20 million of dose.
Astrazeneca is also going to start human trials by August.
So by this Oxford University clinical trials positive result is good news for India.
In a statement, Serum Institue of India CEO Adar Poonawalla said:
“The trials have shown promising results… We will be applying for the licensure trials to the Indian regulator in a week’s time. In addition, we will soon start manufacturing the vaccine in large volumes, the institute will manufacture and supply one billion doses of the vaccine. “
